海外の治験の状況「1」での検索結果
1993件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Authorised
- Does targeting of S1P receptors reduce microglial activation in multiple sclerosis?
- Multiple sclerosis MedDRA version: 14.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders
- Finland
- 2013-11-20
Authorised
- First-line treatment for different subgroups of lymphomas
- Indolent Non-Hodgkin Lymphomas, in particular follicular lymphomas, as well as marginal zone lymphomas, immunocytomas (Waldenström’s macroglobulinaemia) and mantle cell lymphomas;Therapeutic area: Diseases [C] - Cancer [C04]
- Austria, Germany
- 2008-11-20
Authorised
- Does subcutaneous interleukin-1 receptor antagonist reduce inflammation following subarachnoid haemorrhage? - SC IL-1Ra in SAH
- Subarachnoid haemorrhage MedDRA version: 14.0 Level: PT Classification code 10042316 Term: Subarachnoid haemorrhage System Organ Class: 10029205 - Nervous system disorders
- United Kingdom
- 2011-06-23
Authorised
- The additive effect of the appetite hormone GLP-1 (liraglutide) and exercise on maintenance of weight loss and on health parameters after a low calorie diet
- Obesity MedDRA version: 20.0 Level: PT Classification code 10029883 Term: Obesity System Organ Class: 10027433 - Metabolism and nutrition disorders ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Denmark
- 2016-05-11
Authorised
- iVAC-CLL01: Patient-individualized peptide vaccination after first line therapy of CLL
- Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) after first line therapy MedDRA version: 20.0 Level: LLT Classification code 10009310 Term: CLL System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
- Germany
- 2016-04-13
Authorised
- GLP-1 and stroke
- Stroke MedDRA version: 19.1 Level: PT Classification code 10061256 Term: Ischaemic stroke System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Denmark
- 2016-03-22
Authorised
- Pembrolizumab as First Line Treatment in Subjects with Recurrent/Metastatic HNSCC.
- Recurrent/metastatic head and neck squamous cell carcinoma. MedDRA version: 20.0 Level: PT Classification code 10071540 Term: Head and neck cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: PT Classification code 10060121 Term: Squamous cell carcinoma of head and neck System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: PT Classification code 10067821 Term: Head and neck cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Australia, Austria, Brazil, Canada, Chile, Colombia, Czech Republic, Denmark, Estonia, Finland, Germany, Greece, Hong Kong, Hungary, Israel, Italy, Japan, Latvia, Malaysia, Mexico, Netherlands, Norway, Peru, Philippines, Poland, Romania, Russian Federation, Singapore, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, United Kingdom, United States
- 2014-12-22
Authorised
- Rituximab as first-line therapy in lupus nephritis
- Lupus Nephritis MedDRA version: 19.1 Level: PT Classification code 10025140 Term: Lupus nephritis System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
- Belgium
- 2017-04-21
Authorised
- Untersuchungen zur antipsoriatischen Wirkung der UVB-induzierten Synthese von 1alpha, 25-Dihydroxyvitamin D3 (1alpha, 25(OH)2D3, Calcitriol) in Keratinozyten läsionaler psoriatischer Haut unter Verwendung des Cytochrom-P (CYP) Inhibitors Ketokonazol - VITAKET
- Hauptzielvariable ist die klinische Beurteilung der chronisch stationären Psoriasis vulgaris durch den intraindividuellen Vergleich der unterschiedlich behandelten Felder (Feld 1: UVB-Bestrahlung + adäquate, wirkstofffreie Grundlage Nizoral Creme) (Feld 2: UVB-Bestrahlung + Nizoral Creme)( Feld 3: unbehandelt) auf der Grundlage des lokalen PASI-Scores. Unterstützend werden hier die objektiven Parameter OCT und Ultraschall eingesetzt.
- Germany
- 2008-06-19
Authorised
- Study of oral PHA-848125AC in patients with malignant thymoma previously treated with multiple lines of chemotherapy
- Recurrent or metastatic, unresectable B3 thymoma or thymic carcinoma previously treated with multiple lines of chemotherapy;Therapeutic area: Diseases [C] - Cancer [C04]
- Italy, United States
- 2013-02-27
